Recent advances in radiation therapy of pancreatic cancer [version 1; peer review: 2 approved]
Pancreatic cancer has a dismal prognosis with an overall survival outcome of just 5% at five years. However, paralleling our improved understanding of the biology of pancreatic cancer, treatment paradigms have also continued to evolve with newer advances in surgical techniques, chemotherapeutic agen...
Saved in:
Published in | F1000 research Vol. 7; p. 1931 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Faculty of 1000 Ltd
2018
F1000 Research Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Pancreatic cancer has a dismal prognosis with an overall survival outcome of just 5% at five years. However, paralleling our improved understanding of the biology of pancreatic cancer, treatment paradigms have also continued to evolve with newer advances in surgical techniques, chemotherapeutic agents, radiation therapy (RT) techniques, and immunotherapy paradigms. RT dose, modality, fraction size, and sequencing are being evaluated actively, and the interplay between RT and immune effects has opened up newer avenues of research. In this review, we will emphasize recent advances in RT for pancreatic cancer, focusing on preoperative chemoradiation, RT dose escalation, sparing of the spleen to reduce lymphopenia, and combination of RT with immunotherapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-2 No competing interests were disclosed. |
ISSN: | 2046-1402 2046-1402 |
DOI: | 10.12688/f1000research.16272.1 |